Comparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Galera Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
13.81%
EBIT to Interest (avg)
-8.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
1.24%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.38%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.02
EV to EBIT
-24.40
EV to EBITDA
-24.40
EV to Capital Employed
-150.22
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Movement
13What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -6.8 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
PRE-TAX PROFIT(Q)
At USD -1.39 MM has Grown at 61.66%
NET PROFIT(Q)
At USD -1.39 MM has Grown at 59.38%
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 9.7 MM
Here's what is working for Galera Therapeutics, Inc.
Operating Cash Flow
Highest at USD -6.8 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -1.39 MM has Grown at 61.66%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -1.39 MM has Grown at 59.38%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Galera Therapeutics, Inc.
Cash and Eqv
Lowest at USD 9.7 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents






